With the rapid development of modern biotechnology and immunology, the fourth mode of tumor treatment – “biotherapy” has emerged. By mobilizing the specific or non-specific biological immune defense system of the body, biological therapy can stimulate or enhance the anti-tumor immune ability of the tumor patients, which can make up for the shortcomings of the traditional treatment methods, and it has become a new type of tumor treatment mode after surgery, radiotherapy and chemotherapy – the fourth mode of treatment: tumor biological/immunotherapy. Biological immunotherapy is an important direction of tumor treatment in the 21st century, adding a brand new means for tumor treatment. Biological immune cell therapy applying dendritic cells and cytokine-induced killer cells is the most mature representative of tumor immunotherapy technology, and the Ministry of Health has already included this kind of treatment technology in the clinical application catalog of newly added medical items. Biological therapy was pioneered in the early 1990s, and has rapidly developed into a variety of characteristic treatments represented by cytokines, passive cellular immunity (LAK, TIL, CIK), active cellular immunity (DCs), monoclonal antibodies, and gene therapy. Among them, cellular peripheral immunotherapy is to obtain donor lymphocytes that are immune to tumors and transmit them to patients, or to take patients’ own immune cells to activate and proliferate in vitro and then input them into patients, so that they can play anti-tumor roles in patients’ bodies. After more than ten years of development, cellular permissive immunotherapy has become the most actively researched field among the many methods of tumor biotherapy. DC and CIK cells are two groups of cells, which are two parts of tumor immunotherapy, DC recognizes antigen to activate the immune system, while CIK kills tumor cells by exerting cytotoxicity and secreting cytokines, therefore, by combining DC and CIK cells in the treatment of malignant tumors, it is better and more effective to exert systemic anti-tumor effects. Indications: All patients with malignant tumors that meet the inclusion criteria. Including: liver cancer, esophageal cancer, pancreatic cancer, renal cancer, breast cancer, cervical cancer, ovarian cancer, lung cancer (non-small cell), gastric cancer, glioma, prostate cancer, bladder cancer, leukemia (except T-lymphoblastoma). Inclusion Criteria: clinically or pathologically confirmed malignant tumors; Kahlil’s Physical Condition Score of 60 or above; expected survival of at least 6 months; Exclusion Criteria: pregnant or breastfeeding women; vital organ failure: such as cardiac, hepatic, cerebral, renal, and pulmonary failure; transplantation of organs: such as the liver, heart, and kidneys; serious uncontrolled infections; severe allergies. Adverse reactions: transient fever, pain and redness at the injection site, usually subside within 2-3 days without special treatment.